Horlicks Women's Plus: Targeted Communication Strategy in India's Health Food Drinks Category

Industry & Competitive Context

India's Health Food Drinks (HFD) category malted, powdered nutritional beverages consumed mixed with milk or water has historically been dominated by a small set of legacy brands. According to Nielsen data cited in industry reporting, Horlicks held a 52.6% volume market share as of the 2008–09 measurement period, with Bournvita (17.2%), Boost (12.6%), and Complan (12.1%) as its closest rivals. A 2018 RedSeer industry report placed Bournvita as the second-largest player at roughly 15% share, with Complan around 13%, and noted the entry of newer competitors such as Danone's Protinex Grow and Nestlé's relaunched Milo. By 2024, industry estimates reported by Business Standard placed Horlicks' share at around 44%, with Bournvita holding double-digit share and Boost and Complan at roughly 5% each indicating a category that, while still Horlicks-led, had matured and slowed considerably.

This slowdown is well documented. Bloomberg-sourced reporting via Scroll.in noted that after a decade of double-digit growth, HFD sales growth in India fell to 8.6% in 2017, with Euromonitor forecasting a further deceleration to roughly 2.7% by 2022. Analysts quoted in that reporting attributed the slowdown to changing consumer nutrition habits and increased competitive intensity, which was also the stated commercial rationale alongside the Vitamin D deficiency management the acquiring company put across in its public communication behind category incumbents seeking new consolidation and growth avenues.

The most significant structural event in this competitive landscape was Hindustan Unilever Limited's (HUL) acquisition of GlaxoSmithKline Consumer Healthcare's India nutrition business. Announced in December 2018 and completed on 1 April 2020, the all-equity merger brought Horlicks, Boost, Maltova, and Viva into HUL's portfolio; HUL separately paid GSK approximately Rs 3,045 crore (Euro 375.60 million) for exclusive rights to the Horlicks brand for the Indian market, as confirmed in official statements from both HUL and GSK. Coverage in The Week at the time of the deal's announcement noted that the combined Horlicks and Boost portfolio commanded close to 60% share of the HFD category, giving HUL immediate category leadership as it sought to build what the company described as a foods and refreshment business anchored in the "health and wellness" trend.

Within this broader HFD category sits a life-stage sub-segment for adult women's nutrition, in which Horlicks Women's Plus (formerly Women's Horlicks) is positioned as a bone-health-focused specialist product, distinct from the family-oriented "Classic" range and from child-focused variants such as Junior Horlicks.

Brand Situation Prior to Campaign

Women's Horlicks was originally developed and marketed by GSK Consumer Healthcare as a nutritional beverage aimed at adult women's dietary gaps, including calcium and iron. In December 2017, per Exchange4media, GSK Consumer Healthcare (with agency partners FCB Ulka) launched the "Stand Strong" campaign platform, signing actor Taapsee Pannu as the brand's face. Vikram Bahl, then Area Marketing Lead for Nutrition & Digestive Health at GSK Consumer Healthcare India, was quoted describing the #StandStrong platform as targeted primarily at women over 30, intended to build conversation around bone health with a clear call to action toward proactive bone care. In March 2019, the platform was extended through a second phase built around real women in unconventional professions India's first woman commando trainer, first female wildlife naturalist, and a woman dhaki (drum) player with the brand inviting consumers to submit their own "strength" stories under the same #StandStrong hashtag, as reported by Exchange4media. The brand was separately profiled as a case example by the Unstereotype Alliance (a UN Women-linked industry body co-founded with Unilever's backing), which described the "Stand Strong" campaign's explicit goal as breaking from the traditional Indian advertising trope of women depicted only as self-sacrificing daughters, wives, and mothers, replacing it with role models demonstrating agency and physical strength.

Following HUL's 2020 acquisition of the Horlicks brand for India, the product was renamed from "Women's Horlicks" to "Horlicks Women's Plus" a change documented across HUL's own brand website and multiple e-commerce and retail listings (including Apollo Pharmacy and Amazon), which explicitly note the product was "earlier known as Women's Horlicks." Alongside the renaming, HUL's official brand page describes a reformulation under a proprietary "CALSEAL" formula a combination of Calcium, Vitamin D, and Vitamin K2 with the claim that two servings (60g) deliver 100% of the Indian Council of Medical Research (ICMR) 2010 recommended daily allowance of these three nutrients for women. HUL's site further states this formulation is "clinically proven to help improve bone strength in six months," with the referenced clinical basis attributed to a study published in Nutrients (2021;13(2):364) examining the effect of a nutritional beverage on bone turnover markers in young, healthy Indian women.

Strategic Objective

Public statements from HUL executives associated with subsequent campaigns consistently frame the brand's communication objective around two linked goals: (i) raising awareness of Vitamin D deficiency and its causal link to poor bone health among Indian women, and (ii) converting that awareness into a specific, measurable behaviour getting a Vitamin D test as a gateway to habitual nutritional supplementation. Krishnan Sundaram, then Vice President, Nutrition at HUL, described the brand's ambition in a 2022 statement as being to "make a difference to awareness levels and subsequently reduce the burden of Vitamin D deficiency in India," framing HUL's role explicitly as "market leader in women's wellbeing." In a later 2024 statement, Shiva Krishnamurthy, Executive Director of Foods and Refreshment at HUL, articulated the objective in similar terms: creating "bone health awareness among 30+ year-old women" and "driving a culture of preventive healthcare in the country." Taken together, these statements indicate a strategic objective centred on category-level demand generation (expanding the addressable market for a bone-health nutrition product by lowering awareness barriers) rather than on short-term promotional sales activation, executed through cause-linked public health messaging rather than product-attribute advertising alone.

Campaign Architecture & Execution

The brand's public communication since the HUL era has combined three recurring elements: (a) a continuing celebrity brand ambassador platform, (b) an annually renewed healthcare-partner activation offering subsidised or free diagnostic testing, and (c) survey-based public relations content designed to generate earned media around bone health statistics.

On the ambassador front, Taapsee Pannu signed originally under GSK Consumer Healthcare in 2017 was retained as brand ambassador through at least the 2024 iteration of the campaign, per Medianews4u and Impact reporting, indicating unusual continuity of face across the change of parent company and product renaming. Separately, industry trade-press aggregator Sheeko News reported shorter-term influencer collaborations layered onto the core campaign, including a March 2024 collaboration with television actor Shweta Tiwari under the hashtag #HorlicksWomensPlus, and an October 2024 collaboration with lifestyle influencer Shweta Mishra to promote the discounted Vitamin D testing offer.

The diagnostic-partnership element is the most substantively documented piece of the campaign architecture. In January 2022, per Mediabrief and Apollo Clinic's own campaign landing page, Horlicks Women's Plus launched a month-long joint awareness campaign with Apollo Clinics, offering free Vitamin D testing (plus complimentary doctor counselling) to women over 30 across Apollo Clinic locations in Hyderabad, Delhi, Mumbai, Pune, Kolkata, Bengaluru, and Chennai. The same release reported that more than 18,000 women had been tested through the campaign to that point.

This diagnostic partnership was renewed and scaled in subsequent years. In July 2023, the brand released proprietary survey findings commissioned research described as showing that 98% of Indian women experience body aches, with 60% unclear about the underlying cause accompanied by a public statement from Krishnan Sundaram (by then described as Vice President and Business Head, HUL) linking the aches to declining bone density after age 30, as reported by the Free Press Journal. By December 2024, the Apollo partnership had been renewed for a fourth consecutive year, per Medianews4u and Impact, this time under the "Apollo Diagnostics" banner (Apollo's diagnostics arm) rather than Apollo Clinics, offering Vitamin D testing at a reduced price of Rs 199 (down from a stated standard price of Rs 1,850) across more than 2,000 Apollo Diagnostics centres in over 200 cities. That release also cited a 2023 Mompresso survey reporting that 98% of Indian women suffer from body aches and 87% do not recognise the connection to bone health, and quoted Dr Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, stating that approximately 49.9% of Indian women have osteopenia and 18.3% have osteoporosis, and that the multi-year partnership had by then benefited "over 150,000 women" cumulatively through testing.

Positioning & Consumer Insight

Across both the GSK-era "Stand Strong" platform and the HUL-era Apollo partnership, the brand's public communication consistently anchors on a single underlying consumer insight: that bone-health deterioration in Indian women is widespread, under-diagnosed, and misattributed by consumers to unrelated causes. The 2023 and 2024 survey statistics released by the brand high incidence of body aches paired with low consumer awareness of their link to bone or Vitamin D status function as the evidentiary basis for this insight and are repeatedly used in press communication to justify the brand's public-health framing rather than a purely product-benefit framing.

The positioning shift embedded in the "Stand Strong" platform is documented independently by the Unstereotype Alliance case profile, which frames the campaign's explicit intent as countering the historical convention in Indian advertising of depicting women only in duty-bound familial roles, replacing that trope with women in unconventional and physically demanding professions. This represents a positioning move from a purely functional, ingredient-led claim (calcium, iron content) toward an aspirational, identity-linked claim (women's physical and personal strength), while retaining the underlying bone-health functional platform as the connective thread between the emotional and rational elements of the proposition.

The post-2020 architecture under HUL layers a preventive-healthcare positioning on top of this base: rather than positioning the product as a remedy for an already-diagnosed condition, communication frames Vitamin D testing itself as the entry point, with the nutritional product positioned as the ongoing solution once a deficiency or risk is identified. This sequencing diagnose, then supplement is explicit in HUL executive statements across the 2022, 2023, and 2024 releases reviewed.

Media & Channel Strategy

Verified public information on channel strategy is limited to what is disclosed in press releases and trade coverage; no media-mix, spend, or reach-and-frequency data has been publicly disclosed by HUL for this specific brand.

What can be verified is the following: the campaign has relied on (a) celebrity brand ambassador content associated with Taapsee Pannu, continued across multiple years and both corporate parents; (b) offline, in-clinic activation through Apollo Group's clinic and diagnostics network, spanning at least seven major metro cities in the 2022 iteration and expanding to a stated 2,000+ centres across 200+ cities by the 2024 iteration; (c) earned media generated through the release of proprietary or commissioned survey data (the 2023 in-house survey and the cited 2023 Mompresso study) timed to coincide with campaign relaunches; and (d) social-media-linked hashtag campaigns (#StandStrong, #HorlicksWomensPlus) with influencer collaborations reported by trade press in 2024. HUL's own brand website for Horlicks Women's Plus additionally functions as an owned digital channel carrying product education content on the CALSEAL formula and its clinical basis.

No verified public information is available on the campaign's television, digital, or out-of-home media spend, on any paid media GRPs or reach metrics, or on the specific creative agency of record for the post-2020 Apollo-partnership phase of the campaign (FCB Ulka is documented as the agency for the 2017–2019 GSK-era "Stand Strong" work, per Exchange4media bylines, but no subsequent agency credit has been verified in the sources reviewed for this case).

Business & Brand Outcomes

Documented, source-attributable outcomes are confined to the testing-partnership metrics disclosed in company and partner press statements, rather than to sales, share, or profitability outcomes for the brand:

• As of the January 2022 campaign phase, more than 18,000 women had undergone Vitamin D testing through the Horlicks Women's Plus–Apollo Clinics partnership (Mediabrief).

• The July 2023 brand-commissioned survey found that 98% of Indian women reported experiencing body aches, with 60% unclear about the cause (Free Press Journal).

• The December 2024 renewal statement from Apollo Hospitals Group cited that the multi-year partnership had cumulatively benefited more than 150,000 women through testing since inception, and that the 2024 phase of the campaign was projected to reach over 50 million women, though this reach figure is described as an expectation rather than a confirmed, audited outcome (Medianews4u, Impact).

• The partnership between Horlicks Women's Plus and Apollo's clinic/diagnostics network had, as of the December 2024 release, run for four consecutive years, indicating sustained internal commitment to the platform across two different corporate-parent structures (GSK-originated brand relationship carried into HUL ownership).

Strategic Implications

Several strategic patterns are supported by the verified record above. First, the brand's communication strategy illustrates a category-expansion approach to a maturing market: rather than compete primarily on ingredient claims within an already-slowing HFD category (documented at low single-digit growth forecasts by Euromonitor as early as 2018), the brand invested in demand generation for an adjacent, underlying health condition Vitamin D deficiency and bone density decline for which its product is positioned as a downstream solution. This is a documented pattern of using a public-health education platform to build category relevance ahead of, or alongside, product-level selling.

Second, the continuity of the Taapsee Pannu ambassador relationship and the "Stand Strong" positioning language across the change of corporate ownership (from GSK Consumer Healthcare to HUL) suggests that brand equity assets tied to a specific spokesperson and creative platform were treated by the acquiring company as worth preserving rather than replacing wholesale post-acquisition a relevant consideration for M&A-driven brand transitions more broadly, where communication continuity can mitigate consumer-facing disruption even as ownership, formulation ("CALSEAL"), and even product naming ("Women's Horlicks" to "Horlicks Women's Plus") change.

Third, the reliance on a for-profit diagnostics-chain partner (Apollo) as both a distribution channel for the underlying behaviour the brand seeks to encourage (testing) and as a source of third-party-validated statistics used in the brand's own PR (e.g., Dr Sangita Reddy's osteopenia/osteoporosis prevalence figures) represents a documented model of co-branded public-health marketing, in which commercial and preventive-care objectives are explicitly presented as aligned by both parties' spokespeople.

Finally, the absence of any publicly disclosed sales, share, or ROI outcome for this specific brand despite four-plus years of sustained, renewed investment in the same partnership structure is itself a notable feature of the documented record: it indicates that HUL, as a matter of disclosure practice, does not break out sub-brand performance within its Foods & Refreshment segment, which limits the extent to which the campaign's commercial effectiveness can be independently assessed from public sources alone.

Discussion Questions

1. Given that Horlicks Women's Plus's communication strategy centres on raising awareness of an underlying health condition (Vitamin D deficiency) rather than directly promoting product attributes, what are the risks and benefits of this "condition-first" approach compared to a conventional ingredient-led or taste-led FMCG communication strategy?

   
   

2. HUL retained the "Stand Strong" positioning language and the Taapsee Pannu ambassador relationship across its acquisition of the Horlicks brand from GSK, while simultaneously renaming the product and reformulating it under the "CALSEAL" platform. What criteria should an acquiring company use to decide which elements of an acquired brand's communication equity to preserve versus replace?

   
   

3. The brand has partnered with Apollo's clinic and diagnostics network for testing activation over multiple years, with the diagnostics partner also serving as a source of health statistics used in the brand's press communication. What governance considerations should marketers weigh when a commercial partner is also the source of the public-health data underpinning a campaign's core insight?

   
   

4. HUL's public disclosures do not break out financial or market-share performance for Horlicks Women's Plus specifically. From a marketing-accountability standpoint, what alternative, publicly observable indicators (media coverage cadence, partnership renewal, ambassador continuity, survey-based PR cycles) can stakeholders reasonably use to assess whether a sub-brand campaign is meeting its stated objectives in the absence of disclosed commercial metrics?

   
   

5. The Indian Health Food Drinks category has been reported as slowing from double-digit to low-single-digit growth forecasts over the past decade, prompting incumbents to seek adjacent growth levers such as preventive-healthcare positioning. What other life-stage or condition-specific sub-segments within a maturing FMCG category might benefit from a similar "awareness-to-diagnosis-to-supplementation" communication architecture, and what precedent conditions would need to be true (category maturity, credible clinical substantiation, availability of a testing/diagnostic partner) for the model to transfer successfully?